Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Rating of “Buy” by Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been given a consensus rating of “Buy” by the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.1429.

Several brokerages recently weighed in on QNCX. D. Boral Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of Quince Therapeutics in a report on Friday, September 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quince Therapeutics in a research note on Wednesday. Citigroup assumed coverage on shares of Quince Therapeutics in a research note on Tuesday, August 5th. They issued an “outperform” rating on the stock. Citizens Jmp assumed coverage on shares of Quince Therapeutics in a research note on Tuesday, August 5th. They issued a “strong-buy” rating and a $9.00 price target on the stock. Finally, JMP Securities decreased their price target on shares of Quince Therapeutics from $9.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th.

Quince Therapeutics Trading Down 8.3%

Shares of Quince Therapeutics stock opened at $1.87 on Friday. The company has a market capitalization of $100.44 million, a P/E ratio of -1.72 and a beta of 1.07. The company has a debt-to-equity ratio of 1.45, a quick ratio of 5.00 and a current ratio of 5.00. The company has a fifty day moving average of $1.65 and a 200 day moving average of $1.42. Quince Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $2.45.

Quince Therapeutics (NASDAQ:QNCX) last issued its earnings results on Monday, August 11th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). On average, sell-side analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Quince Therapeutics

Hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP purchased a new stake in shares of Quince Therapeutics during the 4th quarter valued at about $57,000. Intellectus Partners LLC purchased a new stake in shares of Quince Therapeutics during the 1st quarter valued at about $71,000. Virtu Financial LLC raised its position in shares of Quince Therapeutics by 48.4% during the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock valued at $58,000 after buying an additional 14,128 shares in the last quarter. Ieq Capital LLC purchased a new stake in shares of Quince Therapeutics during the 1st quarter valued at about $1,073,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Quince Therapeutics during the 2nd quarter valued at about $280,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.